News | July 22, 2023
Lonza delivers 5.6% CER sales growth and 30% CORE EBITDA margin
Good momentum in commercial CDMO business
Good momentum in commercial CDMO business
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
OncoVeryx-F, a proprietary test developed by PredOmix, is set to transform early-stage cancer detection
Approval to dramatically change CAR-T therapies landscape
Cytel excels at using proven quantitative techniques to transform real-world data into actionable insights
Collaboration to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy
PEEK brings a new quality to dental care for patients
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Rapid card test kits for iScreen malaria card antigen (Pf/Pv) & iScreen dengue NS1
Subscribe To Our Newsletter & Stay Updated
